MGMT and anaplastic oligodendroglioma: It was found that methylation of MGMT promoter in anaplastic oligodendroglioma patients predicted better overall survival (OS) and PFS, whether in radiotherapy alone or in sequential radiotherapy and chemotherapy group [chemotherapy regimen: procarbacine, lomustine (CCNU), vincristine (PCV)].